{"id":28255,"date":"2025-04-11T10:29:11","date_gmt":"2025-04-11T08:29:11","guid":{"rendered":"https:\/\/neuro.med.sumdu.edu.ua\/?p=28255"},"modified":"2025-04-11T10:32:41","modified_gmt":"2025-04-11T08:32:41","slug":"fda-approves-pre-filled-syringe-administration-for-fcrn-modulator-efgartigimod","status":"publish","type":"post","link":"https:\/\/neuro.med.sumdu.edu.ua\/en\/fda-approves-pre-filled-syringe-administration-for-fcrn-modulator-efgartigimod\/","title":{"rendered":"FDA Approves Pre-Filled Syringe Administration for FcRn Modulator Efgartigimod"},"content":{"rendered":"<p><a href=\"https:\/\/www.neurologylive.com\/view\/fda-approves-pre-filled-syringe-administration-fcrn-modulator-efgartigimod\" target=\"_blank\" rel=\"noopener\">The FDA has approved a new pre-filled syringe administration route for efgartigimod (Vyvgart; Argenx), a marketed medication for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. The decision offers patients greater convenience and flexibility, allowing in-home administration and reducing the number of time-consuming trips that typically come with intravenous infusions.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The FDA has approved a new pre-filled syringe administration route for efgartigimod (Vyvgart; Argenx), a marketed medication for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. The decision offers patients greater convenience and flexibility, allowing in-home administration and reducing the number of time-consuming trips that typically come with intravenous infusions.<\/p>\n","protected":false},"author":7,"featured_media":28253,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[655],"tags":[],"class_list":["post-28255","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/neuro.med.sumdu.edu.ua\/en\/wp-json\/wp\/v2\/posts\/28255","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/neuro.med.sumdu.edu.ua\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/neuro.med.sumdu.edu.ua\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/neuro.med.sumdu.edu.ua\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/neuro.med.sumdu.edu.ua\/en\/wp-json\/wp\/v2\/comments?post=28255"}],"version-history":[{"count":2,"href":"https:\/\/neuro.med.sumdu.edu.ua\/en\/wp-json\/wp\/v2\/posts\/28255\/revisions"}],"predecessor-version":[{"id":28257,"href":"https:\/\/neuro.med.sumdu.edu.ua\/en\/wp-json\/wp\/v2\/posts\/28255\/revisions\/28257"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/neuro.med.sumdu.edu.ua\/en\/wp-json\/wp\/v2\/media\/28253"}],"wp:attachment":[{"href":"https:\/\/neuro.med.sumdu.edu.ua\/en\/wp-json\/wp\/v2\/media?parent=28255"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/neuro.med.sumdu.edu.ua\/en\/wp-json\/wp\/v2\/categories?post=28255"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/neuro.med.sumdu.edu.ua\/en\/wp-json\/wp\/v2\/tags?post=28255"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}